Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $7.0 million.
- Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization rose 90.26% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 90.26%. This contributed to the annual value of $7.7 million for FY2024, which is 5256.51% up from last year.
- Latest data reveals that Crinetics Pharmaceuticals reported Accumulated Depreciation & Amortization of $7.0 million as of Q3 2025, which was up 90.26% from $9.6 million recorded in Q2 2025.
- In the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $9.6 million in Q2 2025 and a low of $2.9 million during Q1 2021
- Its 5-year average for Accumulated Depreciation & Amortization is $5.3 million, with a median of $4.7 million in 2023.
- Over the last 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization had its largest YoY gain of 5772.18% in 2025, and its largest YoY loss of 90.26% in 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $3.5 million in 2021, then grew by 17.36% to $4.1 million in 2022, then grew by 24.09% to $5.1 million in 2023, then surged by 52.57% to $7.7 million in 2024, then decreased by 8.91% to $7.0 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $7.0 million for Q3 2025, versus $9.6 million for Q2 2025 and $8.6 million for Q1 2025.